Coya Therapeutics (COYA) Return on Capital Employed (2023 - 2026)
Coya Therapeutics (COYA) posted Return on Capital Employed of 46.85% for Q1 2026, up 27.04% sequentially from 64.21% in Q4 2025, and up 565.0% YoY from 7.05% in Q1 2025.
Coya Therapeutics (COYA) Return on Capital Employed (2023 - 2026) Analysis & Trends
Coya Therapeutics has reported Return on Capital Employed for 4 years, with the latest figure at 46.85% in Q1 2026.
- Quarterly Return on Capital Employed rose 565.0% year-over-year to 46.85% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 46.85% (up 565.0% YoY) and the FY2025 annual result came in at 54.64%, down 1039.0% from the prior year.
- Return on Capital Employed rose to 46.85% in Q1 2026 per COYA's latest filing, from 64.21% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 29.95% in Q1 2024 and troughed at 103.04% in Q3 2023.
- A 4-year average of 58.0% and a median of 52.5% in 2025 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2024 and 2025: Return on Capital Employed surged 7099 bps in 2024, then plunged 4194 bps in 2025.
- Over 4 years, Return on Capital Employed stood at 36.71% in 2023, then plunged by 30 bps to 47.75% in 2024, then tumbled by 34 bps to 64.21% in 2025, then climbed by 27 bps to 46.85% in 2026.
- According to Business Quant data, Return on Capital Employed over the past three periods registered 46.85%, 64.21%, and 70.85% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -38.20% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 13.68% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 26.09% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -6.85% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -50.93% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 7.88% |
| 10 | Coya Therapeutics | 113.53 Mn | 70.33 Mn | - | -49.49% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -49.49% |
| Mar 31, 2026 | -46.85% |
| Dec 31, 2025 | -64.21% |
| Sep 30, 2025 | -70.85% |
| Jun 30, 2025 | -71.98% |
| Mar 31, 2025 | -52.50% |
| Dec 31, 2024 | -47.75% |
| Sep 30, 2024 | -32.05% |
| Jun 30, 2024 | -30.05% |
| Mar 31, 2024 | -29.95% |
| Dec 31, 2023 | -36.71% |
| Sep 30, 2023 | -103.04% |
| Jun 30, 2023 | -73.49% |
| Mar 31, 2023 | -94.60% |